FOXO Technologies Reports 63% Revenue Growth to $5.2 Million in Q1 2026

FOXO Technologies Inc. reported a significant increase in net revenues for the first quarter of 2026, reaching $5.2 million, compared to $3.2 million in the same period of 2025, marking a 63% increase. This growth was primarily driven by contributions from its Healthcare segment, particularly from Rennova Community Health, Inc. (RCHI), which saw a revenue increase of approximately $1.5 million due to enhanced swing-bed patient services. The Life Science Services segment, which includes the recently acquired Vector BioSource, contributed about $0.4 million to the revenue growth. Despite the increase in revenues, the company reported a net loss attributable to FOXO of $1.5 million for the quarter, a substantial rise from the $0.6 million loss recorded in the prior year.

Operating expenses also increased, totaling $5.4 million for the first quarter of 2026, up from $4.7 million in the previous year. The direct costs of revenue rose to $2.5 million, reflecting the operational costs associated with the new Vector acquisition and increased activity in the Healthcare segment. Selling, general, and administrative expenses saw a slight increase, attributed to the operational costs of Vector and corporate expenses. The loss from operations improved significantly, decreasing by 82% to $276,851, compared to a loss of $1.5 million in the same quarter of 2025.

FOXO's balance sheet as of March 31, 2026, showed total assets of $45.8 million, a slight increase from $44.6 million at the end of 2025. However, the company faced a working capital deficit of $27.1 million, which raises concerns about its liquidity. Cash and cash equivalents decreased to $65,896 from $207,453 at the end of the previous year. The company’s total liabilities increased to $36.2 million, up from $33.5 million, primarily due to increased notes payable and accrued expenses.

Strategically, FOXO has been active in expanding its operations through acquisitions, including the purchase of Vector in September 2025, which is expected to enhance its capabilities in the life sciences sector. The company is also focused on improving its operational efficiency and revenue generation to address its liquidity challenges. Management has indicated that securing additional capital will be crucial for sustaining operations and funding future growth initiatives. The company is exploring various avenues for capital raising, including equity and debt financing, to support its business strategy.

Looking ahead, FOXO Technologies faces significant challenges, including the need to improve its cash flow and address its working capital deficit. The company has expressed concerns about its ability to continue as a going concern without securing additional financing. Management is actively pursuing strategies to enhance revenue and reduce losses, but the uncertainty surrounding market conditions and regulatory developments poses risks to its operational plans.